|
1
|
Giuliano AR, Palefsky JM, Goldstone S,
Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H,
Hillman R, et al: Efficacy of quadrivalent HPV vaccine against HPV
Infection and disease in males. N Engl J Med. 364:401–411.
2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Palefsky JM, Giuliano AR, Goldstone S,
Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F,
Stoler MH, et al: HPV vaccine against anal HPV infection and anal
intraepithelial neoplasia. N Engl J Med. 365:1576–1585.
2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Markowitz LE, Meites E and Unger ER: Two
vs three doses of human papillomavirus vaccine: New policy for the
second decade of the vaccination program. JAMA. 316:2370–2372.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Meites E, Kempe A and Markowitz LE: Use of
a 2-dose schedule for human papillomavirus vaccination-updated
recommendations of the advisory committee on immunization
practices. MMWR Morb Mortal Wkly Rep. 65:1405–1408. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gertig DM, Brotherton JM and Saville M:
Measuring human papillomavirus (HPV) vaccination coverage and the
role of the national HPV vaccination program register, Australia.
Sex Health. 8:171–178. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Human papillomavirus vaccines: WHO
position paper, May 2017. Wkly Epidemiol Rec. 92:241–268.
2017.PubMed/NCBI(In English, French).
|
|
7
|
Mikamo H, Yamagishi Y, Murata S, Yokokawa
R, Han SR, Wakana A, Sawata M and Tanaka Y: Efficacy, safety, and
immunogenicity of a quadrivalent HPV vaccine in Japanese men: A
randomized, phase 3, placebo-controlled study. Vaccine.
37:1651–1658. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Goldstone S, Giuliano A, Palefsky J and
Luxembourg A: Long-term effectiveness and immunogenicity of
quadrivalent HPV vaccine in young men: 10-year end-of study
analysis. J Clin Oncol. 36 (15 Suppl)(S1553)2018.
|
|
9
|
Patel C, Brotherton JM, Pillsbury A,
Jayasinghe S, Donovan B, Macartney K and Marshall H: The impact of
10 years of human papillomavirus (HPV) vaccination in Australia:
What additional disease burden will a nonavalent vaccine prevent?
Euro Surveill. 23(1700737)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Baricevic I, He X, Chakrabarty B, Oliver
AW, Bailey C, Summers J, Hampson L, Hampson I, Gilbert DC and
Renehan AG: High-sensitivity human papilloma virus genotyping
reveals near universal positivity in anal squamous cell carcinoma:
Different implications for vaccine prevention and prognosis. Eur J
Cancer. 51:776–785. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Public Health England (PHE): Producing
estimates of the size of the LGB population of England. PHE,
London, 2017. Available from: https://www.gov.uk/government/publications/producing-estimates-of-the-size-of-the-lgb-population-of-england.
|
|
12
|
Edelstein M, Iyanger N, Hennessy N, Mesher
D, Checchi M, Soldan K, McCall M, Nugent J, Crofts J, Lo J, et al:
Implementation and evaluation of the human papillomavirus (HPV)
vaccination pilot for men who have sex with men (MSM), England,
April 2016 to March 2017. Euro Surveill. 24(1800055)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Adjei Boakye E, Lew D, Muthukrishnan M,
Tobo BB, Rohde RL, Varvares MA and Osazuwa-Peters N: Correlates of
human papillomavirus (HPV) vaccination initiation and completion
among 18-26 year olds in the United States. Hum Vaccin Immunother.
14:2016–2024. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Soe NN, Ong JJ, Ma X, Fairley CK, Latt PM,
Jing J, Cheng F and Zhang L: Should human papillomavirus
vaccination target women over age 26, heterosexual men and men who
have sex with men? A targeted literature review of
cost-effectiveness. Hum Vaccin Immunother. 14:3010–3018.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pearson AL, Kvizhinadze G, Wilson N, Smith
M, Canfell K and Blakely T: Is expanding HPV vaccination programs
to include school-aged boys likely to be value-for-money: A
cost-utility analysis in a country with an existing school-girl
program. BMC Infect Dis. 14(351)2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Elbasha EH and Dasbach EJ: Impact of
vaccinating boys and men against HPV in the United States. Vaccine.
28:6858–6867. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chessona HW, Ekwueme DU, Saraiyab M,
Dunnea EF and Markowitza LE: The cost-effectiveness of male HPV
vaccination in the United States. Vaccine. 29:8443–8450.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Laprise JF, Drolet M, Boily MC, Jit M,
Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagón T and Brisson
M: Comparing the cost-effectiveness of two- and three-dose
schedules of human papillomavirus vaccination: A
transmission-dynamic modeling study. Vaccine. 32:5845–5853.
2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Isaranuwatchai W, Graham DM, Siu LL and
Hoch JS: Could the human papillomavirus vaccination be
cost-effective in males for the prevention of oropharyngeal cancer?
Expert Rev Pharmacoecon Outcomes Res. 14:763–765. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sinisgalli E, Bellini I, Indiani L, Sala
A, Bechini A, Bonanni P and Boccalini S: HPV vaccination for boys?
A systematic review of economic studies. Epidemiol Prev. 39 (Suppl
1):S51–S58. 2015.PubMed/NCBI
|
|
21
|
Durhama DP, Ndeffo-Mbah ML, Skrip LA,
Jones FK, Bauch CT and Galvani AP: National- and state-level impact
and cost-effectiveness of nonavalent HPV vaccination in the United
States. Proc Natl Acad Sci USA. 113:5107–5112. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Graham DM, Isaranuwatchai W, Habbous S, de
Oliveira C, Liu G, Siu LL and Hoch JS: A cost-effectiveness
analysis of human papillomavirus vaccination of boys for the
prevention of oropharyngeal cancer. Cancer. 121:1785–1792.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chesson HW, Markowitz LE, Hariri S,
Ekwueme DU and Saraiya M: The impact and cost-effectiveness of
nonavalent HPV vaccination in the United States: Estimates from a
simplified transmission model. Hum Vaccin Immunother. 12:1363–1372.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Haeussler K, Marcellusi A, Mennini FS,
Favato G, Picardo M, Garganese G, Bononi M, Costa S, Scambia G,
Zweifel P, et al: Cost-effectiveness analysis of universal human
papillomavirus vaccination using a dynamic bayesian methodology:
The BEST II study. Value Health. 18:956–968. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Boiron L, Joura E, Largeron N, Prager B
and Uhart M: Estimating the cost-effectiveness profile of a
universal vaccination programme with a nine-valent HPV vaccine in
Austria. BMC Infect Dis. 16(153)2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sharma M, Sy S and Kim JJ: The value of
male human papillomavirus vaccination in preventing cervical cancer
and genital warts in a low-resource setting. BJOG. 123:917–926.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jach R, Basta A, Kotarski J, Markowska J,
Paszkowski T, Dębski R, Rokita W, Kędzia W and Kiszka K: Ten years
of anti-HPV vaccinations: What do we know? Prz Menopauzalny.
15:170–175. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ali H, Donovan B, Wand H, Read TR, Regan
DG, Grulich AE, Fairley CK and Guy RJ: Genital warts in young
Australians five years into national human papillomavirus
vaccination programme: National surveillance data. BMJ.
346(f2032)2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Baandrup L, Blomberg M, Dehlendorff C,
Sand C, Andersen KK and Kjaer SK: Significant decrease in the
incidence of genital warts in young Danish women after
implementation of a national human papillomavirus vaccination
program. Sex Transm Dis. 40:130–135. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chessona HW, Meites E, Ekwueme DU, Saraiya
M and Markowitz LE: Cost-effectiveness of nonavalent HPV
vaccination among males aged 22 through 26 years in the United
States. Vaccine. 36:4362–4368. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kwan TT, Tam KF, Lee PW, Lo SS, Chan KK
and Ngan HY: De-stigmatising human papillomavirus in the context of
cervical cancer: A randomised controlled trial. Psychooncology.
19:1329–1339. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
32
|
Chaturvedi AK, Engels EA, Pfeiffer RM,
Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M,
Cozen W, et al: Human papillomavirus and rising oropharyngeal
cancer incidence in the United States. J Clin Oncol. 29:4294–4301.
2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Senkomago V, Henley SJ, Thomas CC, Mix JM,
Markowitz LE and Saraiya M: Human papillomavirus-attributable
cancers-United States, 2012-2016. MMWR Morb Mortal Wkly Rep.
68:724–728. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Qendri V, Bogaards JA and Berkhof J: Who
will benefit from expanding HPV vaccination programs to boys? JNCI
Cancer Spectr. 2(pky076)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kim JJ: A cost-effectiveness analysis of
targeted HPV vaccination of men who have sex with men in the United
States. Lancet Infect Dis. 10:845–852. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Garnett GP: Role of herd immunity in
determining the effect of vaccines against sexually transmitted
disease. J Infect Dis. 191 (Suppl 1):S97–S106. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
37
|
Canfell K, Chesson H, Kulasingam SL,
Berkhof J, Diaz M and Kim JJ: Modeling preventative strategies
against human papillomavirus-related disease in developed
countries. Vaccine. 30 (Suppl 5):F157–F167. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hoefer L, Tsikis S, Bethimoutis G,
Nicolaidou E, Paparizos V, Antoniou C, Kanelleas A, Chardalias L,
Stavropoulos GE, Schneider J and Charnot-Katsikas A: HPV vaccine
acceptability in high-risk Greek men. Hum Vaccin Immunother.
14:134–139. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Herroelen L, de Keyser J and Ebinger G:
Central-nervous-system demyelination after immunisation with
recombinant hepatitis B vaccine. Lancet. 338:1174–1175.
1991.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Colafrancesco S, Perricone C, Tomljenovic
L and Shoenfeld Y: Human papilloma virus vaccine and primary
ovarian failure: Another facet of the autoimmune/inflammatory
syndrome induced by adjuvants. Am J Reprod Immunol. 70:309–316.
2013.PubMed/NCBI View Article : Google Scholar
|
